MAPT and Alzheimer disease: Numerous studies show that cerebral spinal fluid (CSF) Aβ42 levels decrease to around half the level in controls while CSF tau and p181tau levels increase around 2-3 fold in mild-moderate AD patients compared to age-matched controls (e.g. [3,4,5]).